Cellectar Biosciences

Learn more about the pediatric HGG clinical study at

[BioForward @BioForward]

NEW: Wisconsin-based @NMRadioisotopes will partner with @CellectarBio 🌟

This new partnership will integrate NorthStar's Ac-225 into Cellectar's proprietary PLE delivery platform for groundbreaking cancer treatments.

#Biotech #CancerResearch #WisconsinInnovation

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 https://t.co/G8TJn2H0y9 $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences and @SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer https://t.co/mizirMBl26

[Cellectar Biosciences @CellectarBio]

Today, around the U.S., we pause to honor the service and sacrifice of our veterans. At Cellectar Biosciences, we are grateful for those who have bravely served our country and are proud to support our nation's heroes.💙❤️

#VeteransDay #SupportOurVeterans #Community $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

https://t.co/908lQW4pmk #ConferenceCall #Cellectar $CLRB

[Cellectar Biosciences @CellectarBio]

Do you or someone you love have #HighGradeGlioma? Please consider our #PediatricClinicalTrial:
https://t.co/G8ACrMMTiY. Check out @TeamJack for more information about childhood brain cancer. #endbraintumors #CancelChildhoodCancer #pediatricbraintumor #curethekids $CLRB

[Cellectar Biosciences @CellectarBio]

If your child has been diagnosed with High-Grade Glioma, ask your doctor about our clinical trial for #HGG at https://t.co/G8ACrMMTiY. Thank you to @PCRF_Kids for this very informative infographic. #PediatricBrainCancer #defeatDIPG #ChildhoodCancer $CLRB

[Cellectar Biosciences @CellectarBio]

🧬 Amazing talks and insights on Waldenstrom's at the IWWM Conference this week. Every step in research brings us closer advances for patient care! #IWWM2024 #CancerResearch #Prague #WMResearch #WaldenstromsMacroglobulinemia #Lymphoma $CLRB

[Cellectar Biosciences @CellectarBio]

Excited to have attended #IWWM2024 in Prague! Experts from around the world shared new research on Waldenstrom’s Macroglobulinemia, a rare type of lymphoma. Progress is being made, and we’re proud to be a Gold Sponsor for this event! #WMResearch #CancerCare #RareDiseases $CLRB

[Cellectar Biosciences @CellectarBio]

We are energized to attend the 2024 ASTRO Annual Meeting in Washington DC. Learn more about Cellectar Biosciences and our PDC Platform at booth 2145! #WeWhoCurie #RadOnc $CLRB

[Cellectar Biosciences @CellectarBio]

Our commitment to the Radiation Oncology community is rooted in collaboration and partnership. Cellectar is proud to be a gold sponsor for the #ASTRO2024 Annual Meeting. Learn more about our PDC platform at https://t.co/PHWTKZ8iof. $CLRB @ASTRO_org #GoldSponsorship

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences is committed to
solving challenges in pediatric cancer – learn about our
#HighGradeGlioma trial now enrolling
#PediatricCancerAwarenessMonth
https://t.co/ESd22rYXeu #HGG
#DIPG #braincancer #Childrenscancer #pediatriccancer #PediatricBrainCancer $CLRB

[Cellectar Biosciences @CellectarBio]

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia https://t.co/FV7ce0RRFB #IWWM12 #Waldenstroms #Presentations #Oncology #ClinicalResearch #BloodCancer $CLRB

[Cellectar Biosciences @CellectarBio]

James Caruso of Cellectar Biosciences discusses the company's breakthrough PDC technology and upcoming pivotal data, in this interview with @SeekingAlpha . Big things ahead! https://t.co/HeY8kuMO8B #Pharma #HealthcareInnovation $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update https://t.co/inVpOTdXWl #biopharma #radiopharmaceuticals #iopofosine #conferencecall #corporateupdate $CLRB

[Cellectar Biosciences @CellectarBio]

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 https://t.co/SeLEfkEPhE #SecondQuarter #ConferenceCall $CLRB

[Cellectar Biosciences @CellectarBio]

Today, our CEO, Jim Caruso, additional company leadership, and key investigators will share a comprehensive overview of recent data from the CLOVER-WaM pivotal study during a conference call at 8:00 am EDT. For more information, visit: https://t.co/4pL4tEoYOu #KOLCall $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million. https://t.co/DlyCeAzitb #Funding #Biopharma #Iopofosine #Waldenstroms #CLOVERWaM $CLRB

[Cellectar Biosciences @CellectarBio]

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its #CLOVERWaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape: https://t.co/4pL4tEoYOu #clinicalresearch #waldenstroms #iopofosine #marketlandscape #KOLEvent $CLRB

[Cellectar Biosciences @CellectarBio]

We are excited to attend the 2024 SNMMI meeting in Toronto. Come learn more about Cellectar Biosciences at booth #1700! #SNMMIAnnualMeeting #SNMMI2024 #Toronto #NuclearMedicine #Radiotherapeutics @SNM_MI #RadOnc #NucMed $CLRB